Background Intrahepatic recurrence of hepatocellular carcinoma (HCC) following resection
is common. However, no current consensus guidelines exist to inform management …

Primary liver cancer includes hepatocellular carcinoma (HCC, 75–85%) and intrahepatic
cholangiocarcinoma (10–15%). The vast majority of patients with primary HCC are not …

Resistance to radiotherapy (IR), with consequent disease recurrence, continues to limit the
efficacy of contemporary anticancer treatment for patients with hepatocellular carcinoma …

Hepatocellular carcinoma (HCC) is the fifth most common cancer, and its incidence is
rapidly increasing in North America and Western Europe as well as South-East Asia …

The concept of harnessing protons as an anticancer therapy was first proposed in 1946 by
Robert R. Wilson, physicist at the Harvard cyclotron, who posited that protons' unique …

Over the past decade, numerous studies have attempted to enhance the effectiveness of
radiotherapy (external beam radiotherapy and internal radioisotope therapy) for cancer …

Background For patients with hepatocellular carcinoma (HCC) with microvascular invasion
(MVI) after curative resection, the effects of various postoperative adjuvant therapies are not …

Background Atezolizumab plus bevacizumab (atezo-bev) has been recommended for
advanced hepatocellular carcinoma (HCC). High-dose external beam radiotherapy (RT) is …

Background liver cancer is one of the most common cancers in the world. So far, there is no
gold standard treatment for hepatocellular carcinoma. We conducted this in vitro study to …

The treatment planning for patients with hepatocellular carcinoma (HCC) relies
predominantly on tumor burden, clinical performance, and liver function test results. Curative …